Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. (Q37877173)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

title

Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

main subject

metastatic breast cancer

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Anastasia G Eleftheraki

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

H P Kalofonos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

E Razis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

V Kotoula

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

K Pavlakis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

P Papakostas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

G Aravantinos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

G Rigakos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

I Efstratiou

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

K Petraki

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

D Bafaloukos

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

I Kostopoulos

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

D Pectasides

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

K T Kalogeras

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

D Skarlos

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

G Fountzilas

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

language of work or name

English

0 references

publication date

19 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

1 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

447-456

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21594665%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10549-011-1572-5

1 February 2020

exact match

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Resistance to Trastuzumab in Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1572-5